The field of point-of-care (POC) diagnostics and especially lateral flow diagnostics (LFDs) has had another exciting year post-pandemic, laying further foundations for significant future growth. The global market for POC diagnostics was valued at $36.9 billion in 2023 and $40 billion in 2024, and is expected to reach $65.9 billion by the end of 2029. As we close 2024, it is an opportune moment to reflect on the year’s developments and anticipate what lies ahead for 2025. Below, I’ll explore key innovations and market trends, alongside informed predictions about where the industry is heading.
2024 Year in Review
The need for and acceptance of fast and reliable COVID tests had led to a widespread acceptance and understanding of rapid tests—especially lateral flow assays. Since the pandemic, the “untrained” user population used in trials for CLIA waivers is certainly not as naive as it once was, and CLIA studies not as daunting as they once were. However, that does not negate the absolute need for well-designed and high-performance lateral flow tests. This will continue to promote the shift of healthcare from the doctor’s office or clinic to at-home and over the counter (OTC) self-testing.
In addition, POC testing is also driving an evolution of healthcare in specialized clinical departments or clinics and decreasing their reliance on centralized laboratory testing. This shift aligns with trends toward tiered healthcare and decentralized medical services. As high-throughput devices reach smaller facilities, POCT adapts to meet the specific needs of clinical departments by emphasizing speed, convenience, and cost-effectiveness. This transformation positions POCT to excel in delivering flexible and agile diagnostic solutions.
POCT product development must prioritize tailored solutions to meet the diverse needs of clinical departments. Different use cases, such as maternal and child health, kidney function assessment, and chronic disease management, demand specialized features like peripheral blood testing, wide-range urine indicators, and robust data transmission capabilities. By designing products that align closely with these unique requirements, POCT developers can enhance relevance, usability, and impact in healthcare.
Point-of-need testing remains vital, offering real-time results for urgent care scenarios like ERs and ICUs, while balancing sample complexity with healthcare workflow needs. At the same time, at-home diagnostic tests have advanced, empowering patients with accessible and convenient health monitoring tools. These tests complement traditional care by enabling informed decision-making, easing the burden on healthcare systems, and fostering patient engagement.
Integration with Digital and AI Platforms
The integration of digital technologies into lateral flow devices is another pivotal trend of 2024. Smartphone-based readers as well as highly customized stand-alone LFA readers have allowed users to obtain semi-quantitative or fully quantitative results from traditionally qualitative assays. These technologies not only have the potential to improve diagnostic accuracy but also enable real-time data sharing for epidemiological tracking and disease management.
The use of artificial intelligence (AI)-driven image analysis has also allowed development of more informative and accurate algorithms that enable unprecedented data collection and analysis. AI is already transforming medical applications, particularly in medical imaging, where it aids in detecting anomalies often imperceptible to the human eye. As AI, connected health, and rapid diagnostics advance, their development is becoming increasingly intertwined especially in the development of diagnostic tools. While the live use of AI in clinical diagnosis will no doubt be a highly debated topic in the years to come with accompanying regulatory challenges, its use in diagnostic tool development serves as a bridge between traditional POC testing and emerging at-home diagnostics, enhancing accuracy, efficiency, and integration across healthcare solutions.
Next Gen Diagnostics and Data Sharing versus Privacy
While the revolution in diagnostics excites many, widespread data collection and sharing, especially in healthcare, raises significant privacy concerns. However, ethical data-sharing practices are essential for advancing next-generation diagnostics, scientific discoveries, and technological innovation. Companies must prioritize informed consent, data security, patient anonymity, transparency, and responsible beta testing.
Given the sensitive nature of health records, their privacy is paramount and protected by regulations, but technological advancements often outpace policies. All stakeholders must ensure responsible data use, balancing ethical considerations with progress. Risks, such as insecure storage and unintended sharing through healthcare apps, highlight the need for proactive measures during device development. By addressing these challenges and fostering ethical discussions among patients, providers, and researchers, the integration of diagnostics with electronic medical records can be achieved responsibly.
The use and integration of AI systems further the need for responsible use and protection of data. AI systems require vast amounts of data, making them attractive targets for cyberattacks. Poor encryption protocols during data transfer or storage can lead to breaches. Even the potential for anonymized data to be reverse-engineered may be possible allowing individuals to be identified thereby violating their privacy.
That is why there must be a concerted effort to implement and enforce robust data protection laws, such as GDPR or HIPAA, to ensure compliance. In addition the introduction and use of cybersecurity in all instrumentation including the aforementioned LFA readers.
Commercialization and Market Dynamics for Lateral Flow Assays
The lateral flow diagnostics market continued its robust growth in 2024, with revenues between $10 and $15 billion, depending on the analyst. This expansion has been fueled by increasing applications in infectious disease diagnostics, as well as emerging uses in oncology, environmental monitoring, and veterinary medicine.
At the same time, diagnostic preparedness for non-COVID infectious diseases remains a critical challenge. FIND’s 2024 readiness index highlighted glaring diagnostic shortages for diseases like tuberculosis and malaria. These shortages have placed significant pressure on assay developers to innovate rapidly and meet urgent needs in resource-limited settings. The lack of reliable point-of-care diagnostics for tuberculosis creates barriers to timely treatment exacerbates public health challenges. Current assays often face limitations in sensitivity, particularly for detecting low bacterial loads in extrapulmonary or pediatric TB cases. Scalability and affordability also remain significant hurdles, as many existing diagnostics are too costly or complex for deployment in resource-limited settings. However, this gap also presents opportunities for developers to design assays tailored for low-resource environments, such as multiplexed LFAs that combine affordability with high sensitivity. Collaborations with global health organizations and targeted funding mechanisms could accelerate progress in this critical area. This should stress the importance of diversifying R&D investments to address global health priorities beyond pandemic response.
Industry Events and Collaborations
The Advanced Lateral Flow Conference (ALFC) 2024, themed “Flow Forward,” brought together thought leaders to discuss emerging technologies and regulatory challenges. Notable sessions focused on the integration of machine learning algorithms and harmonizing global regulatory pathways for lateral flow diagnostics. The conference emphasized the importance of sustainability in diagnostics—a topic poised to gain even more attention in 2025.
Predictions for 2025: Shaping the Future of Lateral Flow Diagnostics
As we look ahead to 2025, I can’t help but feel optimistic about what’s in store for the lateral flow diagnostics industry. Call it a New Year’s wish list for developers, researchers, and industry stakeholders, but many of these predictions are grounded in the exciting momentum we built over the last 2-3 years and especially in 2024. While some may seem ambitious, I firmly believe the progress we’ve seen in lateral flow diagnostics puts us on the brink of transformational breakthroughs. Let’s dive into what I hope to see—and what I predict will come to fruition—in the year ahead.
1. Broader Integration with Digital Ecosystems
Digital transformation in diagnostics will accelerate in 2025, with more manufacturers incorporating cloud-based platforms into their LFA products. These platforms will not only facilitate real-time disease surveillance but also improve patient management by integrating with electronic health records (EHRs). Regulatory challenges for these platforms often include demonstrating consistent analytical performance across varied user environments, ensuring data security in cloud-based integrations, and navigating the classification of AI software under existing medical device regulations. Overcoming these hurdles will require closer collaboration between developers and regulatory agencies, alongside robust validation studies tailored to address the unique complexities of AI-driven diagnostics.
2. Sustainability as a Core Focus
Sustainability will emerge as a central theme in diagnostic development. Examples include the adoption of biodegradable nitrocellulose membranes and the use of biodegradable or compostable housings for lateral flow devices. Additionally, several manufacturers are experimenting with energy-efficient production processes and sourcing raw materials from renewable resources. These efforts not only reduce environmental impact but also align with increasing global emphasis on eco-friendly healthcare solutions. This includes the adoption of biodegradable materials for assay components and the design of eco-friendly manufacturing processes. At ALFC 2025 (as in 2024), we anticipate extensive discussions on reducing the environmental footprint of diagnostics while maintaining affordability and accessibility.
(For more on this important issue, I invite you to watch DCN Dx’s Industrial Designer’s discussion on this topic here.)
3. New Market Opportunities for LFDs
The growing demand for decentralized testing will drive innovations in lateral flow technology for chronic disease monitoring and personalized medicine. For example, we foresee the development of LFAs for monitoring wellness biomarkers associated with general health trends, such as blood glucose or cholesterol levels, enabling individuals to track their health more effectively at home without direct medical oversight. While the use of LFAs for regulated healthcare applications, like cardiovascular or stroke markers, may face regulatory hurdles that ultimately can be overcome, In addition the focus on wellness diagnostics could offer an alternative pathway for commercialization for certain tests.
4. Regulatory Harmonization and Global Deployment
2025 will see significant progress in harmonizing regulatory frameworks for lateral flow diagnostics. While the implementation of the IVDR rules in the EU has caused significant hurdles for market entry, it does make to more stable and well understood US FDA regulations become more attractive for market entry.
Building Momentum: Looking Ahead to ALFC 2025
The Advanced Lateral Flow Conference 2025, scheduled for October, promises to be another milestone event for the industry. With talks and panels shaping up to include sustainability, AI integration, and LFA market expansion, ALFC 2025 will serve as a hub for innovation and collaboration. DCN Dx will be proud to contribute our insights on cutting-edge technologies and emerging market trends. Hope to see you there!
Closing Thoughts
The past year has been transformative for lateral flow diagnostics, with advancements that have redefined the potential of this versatile technology. As we enter 2025, the industry stands at the cusp of even greater innovation, driven by the convergence of materials science, digital technology, and global health priorities. At DCN Dx, we are excited to be part of this journey, supporting developers and stakeholders as they bring impactful solutions to market.
Advancements in at-home and point-of-care diagnostic solutions have elevated patient care by improving safety, outcomes, and reducing healthcare costs and resource burdens. Patients now play an active role in monitoring their health, supported by growing options to track and diagnose conditions. Early detection and diagnosis, the cornerstone of prevention and treatment, lead to better outcomes, lower costs, and more equitable healthcare access.
These advancements signify a paradigm shift in medicine, with widespread adoption of diagnostic platforms transforming care delivery. Combined with laboratory-like services for at-home or clinic use, this shift enhances the affordability, accessibility, and effectiveness of medical care for a broad range of diseases, marking a profound cultural and medical evolution.
Promoting universal access to healthcare involves ensuring that the benefits of accessible POC testing are realized globally, in both developed and developing countries. Advocating for widespread diagnostic access and advancing technology in low- to middle-income countries is crucial in combating and preventing devastating disease outbreaks and pandemics. Strong efforts to make diagnostic tools available and affordable will play a key role in improving global health outcomes and strengthening defenses against future health crises.
For lateral flow developers, medtech investors, and researchers, the coming year offers unparalleled opportunities to shape the future of diagnostics. We look forward to continuing this dialogue and fostering collaboration across the industry.
